官方服务：
资源简介：
Database from leukemia and lymphoma patients
白血病（leukemia）与淋巴瘤（lymphoma）患者数据库
应用场景：
创建时间：
2020-12-20
相关数据集
MDM2 polymorphisms and hematological parameters during chemotherapy, raw data and ratios
MDM2 polymorphism status, raw data (hematological parameters) and ratios of hematological parameters for all patients in the DDP trial. Hematological parameters from blood samples collected bef
DataCite Commons2025-01-17 更新100
Comparison characteristics of hematologic cancer cases and individuals without a diagnosed hematologic cancer during study follow-up.
Comparison characteristics of hematologic cancer cases and individuals without a diagnosed hematologic cancer during study follow-up.
NIAID Data Ecosystem40
Additional file 3 of Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
Additional file 3. Clinical Response.
NIAID Data Ecosystem30
Characteristics of the B-ALL patients who experienced hematologic relapse.
data weren’t monitored BM: unfractionated cells of bone marrow. Characteristics of the B-ALL patients who experienced hematologic relapse.
NIAID Data Ecosystem40
Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma
Introduction : Real-world effectiveness of hemato-oncology pharmaceuticals may not necessarily mimic clinical trial efficacy results, mainly due to demographic and clinical practice variability.
DataCite Commons2020-08-26 更新30
